The commercialization of cell and gene therapies raises several complex conversations and questions for employers and payers. Without proper solutions and partnerships, employers and health insurers will be held responsible for extreme medical costs associated with gene therapy.

Anshul Mangal (President, Project Farma) is joined by Philip Cyr (SVP, Precision Value & Health) to provide insight into the process and factors driving the high-ticket price of these life-saving therapies in “A Shared Opportunity: The Future of Cell and Gene Therapy”.

CLICK HERE to read the full article